Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease
- PMID: 30665567
- DOI: 10.1016/j.kint.2018.11.016
Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease
Abstract
Anti-phospholipase A2 receptor (PLA2R) antibody is a specific biomarker for primary membranous nephropathy (MN). Testing positive for anti-PLA2R has been postulated to establish a diagnosis of MN in the absence of a kidney biopsy. Bobart et al. tested this hypothesis and concluded that anti-PLA2R positivity is sufficient to diagnose primary MN and initiate treatment in a subset of patients with nephropathy. This biomarker, however, does not render the kidney biopsy obsolete, but encourages the application of molecular analyses to renal pathology to keep the biopsy relevant.
Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Comment on
-
Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.Kidney Int. 2019 Feb;95(2):429-438. doi: 10.1016/j.kint.2018.10.021. Kidney Int. 2019. PMID: 30665573
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
